Safety and Efficacy Results of Phase I/II SCOOP Trial in mCRC
Akihito Kawazoe, MD, discussed the safety and efficacy results of the phase I/II SCOOP trial of napabucasin plus pembrolizumab for treatment of patients with metastatic colorectal cancer.
Akihito Kawazoe, MD, lead investigator in the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, discussed the safety and efficacy results of the phase I/II SCOOP trial of napabucasin (BBI608) plus pembrolizumab (Keytruda) for treatment of patients with metastatic colorectal cancer (mCRC).
Kawazoe presented these results at the 2018 Gastrointestinal Cancers Symposium. This multicenter study sought to discover the right dose level for napabucasin and to identify the efficacy of this treatment combination.
It was found that the combination of napabucasin plus pembrolizumab was very tolerable with little adverse events. Researchers also found which treatment dose was the most effective. According to the results of this study, patients can most benefit from a napabucasin dose of 480 mg per day.
Read more onthis treatment combination for metastatic colorectal cancer.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
